Amycretin
A Novo Nordisk investigational co-agonist targeting GLP-1 and amylin pathways, now closely watched as a next-wave obesity candidate.
Also referenced as: NNC0487-0111
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.
NNC0487-0111
No FDA label signal · 21 trials · 14 PubMed results
What amycretin is
Amycretin is an investigational single-molecule GLP-1 and amylin receptor agonist being developed by Novo Nordisk for obesity and related metabolic disease.
Why it matters
It is one of the clearer examples of where the obesity pipeline is heading after first-generation GLP-1 therapies. Instead of just extending incretin pharmacology, amycretin combines GLP-1 signaling with amylin-linked satiety in a single molecule.
Regulatory context
Amycretin is not FDA approved. The public human evidence base is still early relative to drugs like semaglutide or tirzepatide, but the compound is now important enough that it belongs in any current obesity-peptide library.
Practical reading note
Amycretin gets talked about like a future blockbuster, but the safest framing is still: high-interest pipeline drug, not established therapy.